Inhibiting Peptidoglycan Hydrolase Alleviates MRSA Pneumonia Through Autolysin-Mediated MDP-NOD2 Pathway

Area of Science:

• Microbiology
• Pharmacology
• Immunology

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) presents significant treatment challenges due to antibiotic resistance.
• Diarylurea ZJ-2 has emerged as a novel antibacterial agent effective against multidrug-resistant Enterococcus faecium.
• Understanding ZJ-2's precise mechanism is crucial for developing new anti-MRSA therapies.

Purpose of the Study:

• To elucidate the bactericidal mechanism of ZJ-2, specifically its role as a peptidoglycan (PG) hydrolase.
• To investigate the impact of ZJ-2 on PG homeostasis mediated by AtlA.
• To evaluate ZJ-2's efficacy in a preclinical model of MRSA pneumonia.

Main Methods:

• Utilized wild-type and ΔatlA mutant strains of MRSA for comparative analysis.
• Employed antimicrobial susceptibility testing, hemolytic toxin assays, microanalysis, and autolysis assays.
• Conducted qRT-PCR, ELISA, and a mouse model of pneumonia to assess molecular and in vivo effects.

Main Results:

• ZJ-2 down-regulated key peptidoglycan hydrolase (PGH) genes (sprX, walR, atlA, lytM).
• Observed reductions in PG, muramyl dipeptide (MDP), cytokines, and hemolytic toxin levels.
• Confirmed similar inhibitory trends in the mouse MRSA pneumonia model, including effects on NOD2 and proinflammatory factors.

Conclusions:

• ZJ-2 functions as a novel inhibitor of PG hydrolysis, disrupting AtlA-mediated PG homeostasis.
• The compound reduces inflammation by down-regulating the muramyl dipeptide-nucleotide oligomerization domain protein 2 (MDP-NOD2) pathway.
• ZJ-2 demonstrates potential as a therapeutic agent for MRSA infections.